Less than one in 10 individuals that would benefit from weight-loss injections including Wegovy can access them, caution the WHO as it issues its initial guidance on the therapies.
Given in excess of 1,000,000,000 people worldwide currently obese, it is urging increased and just access to GLP-1 medication.
According to forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken.
"The latest guidelines affirms that obesity is a chronic disease that can be managed with holistic and lifelong treatment," said WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are major obstacles to widespread availability to the jabs that can aid individuals in losing considerable weight, says the body.
GLP-1 Therapy Scarcity
Even in the present most favorable case, the supply of such drugs could only cover approximately 100 million people – fewer than 10% of the global need, per the WHO.
The guideline calls on nations and manufacturers to widen access, through approaches including voluntary licensing.
A patent on the active ingredient – the core ingredient of a leading brand – is set to lapse in several countries in 2026.
The Way Obesity Injections Function
These medications mimick a biological compound to reduce digestion speed, reduce hunger and enhance satiety so people reduce food intake.
People commonly start to lose weight within a few weeks of commencing the regular doses.
Research suggests people may put most of the weight back on a year later of halting the treatment, when their typical appetite return.
To be above a healthy weight raises your likelihood for contracting health problems, including diabetes, heart disease, brain attack, and specific cancers.
Obesity impacts individuals in all nations and was associated with over three and a half million fatalities worldwide in 2024, as per the health agency.
